Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Largest Shareholders Are Private Companies Who Were Rewarded as Market Cap Surged CN¥478m Last Week

Key Insights Youcare Pharmaceutical Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 52% of the business is

Simply Wall StJul 19 20:01 ET

Youcare Pharmaceutical Group (688658.SH): 245 million restricted shares will be unlocked on July 5th.

On June 27th, Gelonhui reported that Youcare Pharmaceutical Group (688658.SH) announced that the total number of shares of the company's stock listed this time is 245 million. The stock will be listed on July 5, 2024.

Gelonghui FinanceJun 27 05:46 ET

Youcare Pharmaceutical Group Co., Ltd.'s (SHSE:688658) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?

Youcare Pharmaceutical Group's (SHSE:688658) stock is up by a considerable 6.5% over the past month. However, in this article, we decided to focus on its weak fundamentals, as long-term financial pe

Simply Wall StJun 19 23:42 ET

Youcare Pharmaceutical Group (688658.SH) will distribute RMB 2 per 10 shares for 2023, with the registration date being June 24.

Youcare Pharmaceutical Group (688658.SH) announced that the company will distribute equity for the year 2023, at a rate of 10 shares per...

Zhitong FinanceJun 17 06:26 ET

YKYY017, the multi-peptide drug for COVID-19 developed by Youcare Pharmaceutical Group, has made breakthrough progress after completing phase II clinical trials.

Given that the coronavirus will not disappear completely in the short term and is highly likely to coexist with humans in the long term, gradually becoming seasonal and continuing to mutate, there may still be mutant strains in the future with stronger escape ability, faster spread, and higher potential pathogenicity, which poses a far greater threat to human health than common colds and influenza. Therefore, it is still crucial to develop broad-spectrum, effective drugs for coronavirus. The important progress made by Youcare Pharmaceutical Group in the development of the YKYY017 nebulized inhalation peptide drug for preventing and treating novel coronavirus infections has significant implications for the pharmaceutical industry. Another breakthrough in the research and development of COVID-19 drugs.

China InvestorsJun 16 21:59 ET

Yuekang Pharmaceutical (688658.SH): spent a total of 100 million yuan to buy back 1.2264% of the shares

Gelonghui, May 30, 丨 Yuekang Pharmaceutical (688658.SH) announced that as of May 29, 2024, the company had repurchased 5,518,942 shares of the company's shares through a dedicated stock repurchase securities account, accounting for 1.2264% of the company's current total share capital, an increase of 0.2286% compared with the previous disclosure. The highest purchase price was 22.30 yuan/share, and the lowest price was 13.46 yuan/share. The total amount paid was RMB 10,000.94 million.

Gelonghui FinanceMay 30 08:01 ET